Acute generalized exanthematous pustulosis

  • 1  Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968 Dec;80(12):771–93. Cross Ref link Pubmed link
  • 2  Staughton RC, Payne CM, Harper JI, McMichen H. Toxic pustuloderma – a new entity? J R Soc Med 1984;77 Suppl. 4:6–8.
  • 3  Macmillan AL. Generalised pustular drug rash. Dermatologica 1973;146(5):285–91. Cross Ref link Pubmed link
  • 4  Beylot C, Bioulac P, Doutre MS. [Acute generalized exanthematic pustuloses (four cases) (author's translation)]. Ann Dermatol Venereol 1980 Jan–Feb;107(1–2):37–48. Pubmed link
  • 5  Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) – a clinical reaction pattern. J Cutan Pathol 2001 Mar;28(3):113–19. Cross Ref link Pubmed link
  • 6  Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP) – results of a multinational case–control study (EuroSCAR). Br J Dermatol 2007 Nov;157(5):989–96. Cross Ref link Pubmed link
  • 7  Lim CS, Lim SL. Acute generalized exanthematous pustulosis associated with asymptomatic Mycoplasma pneumoniae infection. Arch Dermatol 2009 Jul;145(7):848–9. Pubmed link
  • 8  Feio AB, Apetato M, Costa MM, Sa J, Alcantara J. [Acute generalized exanthematous pustulosis due to Coxsackie B4 virus.] Acta Med Port 1997 Jun–Jul;10(6–7):487–91. Pubmed link
  • 9  Naides SJ, Piette W, Veach LA, Argenyi Z. Human parvovirus B19‐induced vesiculopustular skin eruption. Am J Med 1988 May;84(5):968–72. Cross Ref link Pubmed link
  • 10  Calistru AM, Lisboa C, Cunha AP, Bettencourt H, Azevedo F. Acute generalized exanthematous pustulosis to amoxicillin associated with parvovirus B19 reactivation. Cutan Ocul Toxicol 2012 Sep;31(3):258–61. Cross Ref link Pubmed link
  • 11  Haro‐Gabaldon V, Sanchez‐Sanchez‐Vizcaino J, Ruiz‐Avila P, Gutierrez‐Fernandez J, Linares J, Naranjo‐Sintes R. Acute generalized exanthematous pustulosis with cytomegalovirus infection. Int J Dermatol 1996 Oct;35(10):735–7. Cross Ref link Pubmed link
  • 12  Lerch M, Bircher AJ. Systemically induced allergic exanthem from mercury. Contact Dermatitis 2004 Jun;50(6):349–53. Cross Ref link Pubmed link
  • 13  Makris M, Spanoudaki N, Giannoula F, Chliva C, Antoniadou A, Kalogeromitros D. Acute generalized exanthematous pustulosis (AGEP) triggered by a spider bite. Allergol Int 2009 Jun;58(2):301–3. Cross Ref link Pubmed link
  • 14  Pichler WJ. T cells in drug allergy. Curr Allergy Asthma Rep 2002 Jan;2(1):9–15. Cross Ref link Pubmed link
  • 15  Britschgi M, Steiner UC, Schmid S, et al. T‐cell involvement in drug‐induced acute generalized exanthematous pustulosis. J Clin Invest 2001 Jun;107(11):1433–41. Cross Ref link Pubmed link
  • 16  Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil‐mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2002 Aug;2(4):325–31. Cross Ref link Pubmed link
  • 17  Schmid S, Kuechler PC, Britschgi M, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol 2002 Dec;161(6):2079–86. Cross Ref link Pubmed link
  • 18  Navarini AA, Valeyrie‐Allanore L, Setta‐Kaffetzi N, et al. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol 2013 Jul;133(7):1904–7. Cross Ref link Pubmed link
  • 19  Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011 Sep 9;89(3):432–7. Cross Ref link Pubmed link
  • 20  Setta‐Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis‐associated pustular phenotypes. J Invest Dermatol 2013 May;133(5):1366–9. Cross Ref link Pubmed link
  • 21  Smith K, Norwood C, Skelton H. Do the physical and histologic features and time course in acute generalized exanthematous pustulosis reflect a pattern of cytokine dysregulation? J Cutan Med Surg 2003 Jan–Feb;7(1):7–12. Cross Ref link Pubmed link
  • 22  Ameen M, Smith CH, Barker JN. Pharmacogenetics in clinical dermatology. Br J Dermatol 2002 Jan;146(1):2–6. Cross Ref link Pubmed link
  • 23  Hotz C, Valeyrie‐Allanore L, Haddad C, et al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol 2013 Dec;169(6):1223–32. Cross Ref link Pubmed link
  • 24  Roujeau JC, Bioulac‐Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991 Sep;127(9):1333–8. Cross Ref link Pubmed link
  • 25  Corral de la Calle M, Martin Diaz MA, Flores CR, Vidaurrazaga C. Acute localized exanthematous pustulosis secondary to levofloxacin. Br J Dermatol 2005 May;152(5):1076–7. Cross Ref link Pubmed link
  • 26  Prange B, Marini A, Kalke A, Hodzic‐Avdagic N, Ruzicka T, Hengge UR. [Acute localized exanthematous pustulosis (ALEP).] J Dtsch Dermatol Ges 2005 Mar;3(3):210–12. Pubmed link
  • 27  Tresch S, Cozzio A, Kamarashev J, et al. T cell‐mediated acute localized exanthematous pustulosis caused by finasteride. J Allergy Clin Immunol 2012 Feb;129(2):589–94. Cross Ref link Pubmed link
  • 28  Vickers JL, Matherne RJ, Mainous EG, Kelly BC. Acute localized exanthematous pustulosis: a cutaneous drug reaction in a dental setting. J Am Dent Assoc 2008 Sep;139(9):1200–3. Cross Ref link Pubmed link
  • 29  Betto P, Germi L, Bonoldi E, Bertazzoni M. Acute localized exanthematous pustulosis (ALEP) caused by amoxicillin–clavulanic acid. Int J Dermatol 2008 Mar;47(3):295–6. Cross Ref link Pubmed link
  • 30  Liang CP, Yang CS, Shen JL, Chen YJ. Sorafenib‐induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. Br J Dermatol 2011 Aug;165(2):443–5. Cross Ref link Pubmed link
  • 31  Rastogi S, Modi M, Dhawan V. Acute localized exanthematous pustulosis (ALEP) caused by Ibuprofen. A case report. Br J Oral Maxillofac Surg 2009 Mar;47(2):132–4. Cross Ref link Pubmed link
  • 32  Kim SW, Lee UH, Jang SJ, Park HS, Kang YS. Acute localized exanthematous pustulosis induced by docetaxel. J Am Acad Dermatol 2010 Aug;63(2):e44–6. Cross Ref link Pubmed link
  • 33  Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol 2011 Jan;36(1):6–11. Cross Ref link Pubmed link

Drug reaction with eosinophilia and systemic symptoms

  • 34  Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol [Review] 2011 Jan;36(1):6–11. Cross Ref link Pubmed link
  • 35  Saltzstein SL, Ackerman LV. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically pathologically malignant lymphomas. Cancer 1959 Jan–Feb;12(1):164–82. Cross Ref link Pubmed link
  • 36  Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995 Nov 27;155(21):2285–90. Cross Ref link Pubmed link
  • 37  Callot V, Roujeau JC, Bagot M, et al. Drug‐induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol 1996 Nov;132(11):1315–21. Cross Ref link Pubmed link
  • 38  Sontheimer RD, Houpt KR. DIDMOHS: a proposed consensus nomenclature for the drug‐induced delayed multiorgan hypersensitivity syndrome. Arch Dermatol 1998 Jul;134(7):874–6. Cross Ref link Pubmed link
  • 39  Bocquet H, Bagot M, Roujeau JC. Drug‐induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg [Review] 1996 Dec;15(4):250–7. Cross Ref link Pubmed link
  • 40  Kardaun SH, Sekula P, Valeyrie‐Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013 Nov;169(5):1071–80. Cross Ref link Pubmed link
  • 41  Mallal S, Nolan D, Witt C, et al. Association between presence of HLA‐B*5701, HLA‐DR7, and HLA‐DQ3 and hypersensitivity to HIV‐1 reverse‐transcriptase inhibitor abacavir. Lancet 2002 Mar 2;359(9308):727–32. Cross Ref link Pubmed link
  • 42  Wang J, Zhang J, Wu X, Yu P, Hong Z. HLA‐B*1502 allele is associated with a cross‐reactivity pattern of cutaneous adverse reactions to antiepileptic drugs. J Int Med Res 2012;40(1):377–82. Cross Ref link Pubmed link
  • 43  Zhang Y, Wang J, Zhao LM, et al. Strong association between HLA‐B*1502 and carbamazepine‐induced Stevens–Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol 2011 Sep;67(9):885–7. Cross Ref link Pubmed link
  • 44  Then SM, Rani ZZ, Raymond AA, Ratnaningrum S, Jamal R. Frequency of the HLA‐B*1502 allele contributing to carbamazepine‐induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol 2011 Sep;29(3):290–3. Pubmed link
  • 45  Phillips EJ, Mallal SA. HLA‐B*1502 screening and toxic effects of carbamazepine. N Engl J Med 2011 Aug 18;365(7):672; author reply 3. Cross Ref link Pubmed link
  • 46  Wu XT, Hu FY, An DM, et al. Association between carbamazepine‐induced cutaneous adverse drug reactions and the HLA‐B*1502 allele among patients in central China. Epilepsy Behav 2010 Nov;19(3):405–8. Cross Ref link Pubmed link
  • 47  Genin E, Chen DP, Hung SI, et al. HLA‐A*31:01 and different types of carbamazepine‐induced severe cutaneous adverse reactions: an international study and meta‐analysis. Pharmacogenomics J 2013 June;14(3):281–8. Cross Ref link Pubmed link
  • 48  Ozeki T, Mushiroda T, Yowang A, et al. Genome‐wide association study identifies HLA‐A*3101 allele as a genetic risk factor for carbamazepine‐induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011 Mar 1;20(5):1034–41. Cross Ref link Pubmed link
  • 49  Hung SI, Chung WH, Liou LB, et al. HLA‐B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005 Mar 15;102(11):4134–9. Cross Ref link Pubmed link
  • 50  Chiu ML, Hu M, Ng MH, et al. Association between HLA‐B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol 2012 Jul;167(1):44–9. Cross Ref link Pubmed link
  • 51  Gonçalo M, Coutinho I, Teixeira V, et al. HLA‐B*58:01 is a risk factor for allopurinol‐induced DRESS and Stevens–Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. Br J Dermatol 2013;169(3):660–5. Cross Ref link Pubmed link
  • 52  Camous X, Calbo S, Picard D, Musette P. Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis. Curr Opin Immunol 2012;24(6):730–5. Cross Ref link Pubmed link
  • 53  Pichler WJ, Yawalkar N, Britschgi M, et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol [Research Support, Non‐U.S. Government Review] 2002;3(4):229–38. Cross Ref link Pubmed link
  • 54  Gerber BO, Pichler WJ. Cellular mechanisms of T cell mediated drug hypersensitivity. Curr Opin Immunol 2004 Dec;16(6):732–7. Cross Ref link Pubmed link
  • 55  Kish DD, Volokh N, Baldwin WM, 3rd, Fairchild RL. Hapten application to the skin induces an inflammatory program directing hapten‐primed effector CD8 T cell interaction with hapten‐presenting endothelial cells. J Immunol 2011 Feb 15;186(4):2117–26. Cross Ref link Pubmed link
  • 56  Pichler WJ. Pharmacological interaction of drugs with antigen‐specific immune receptors: the p‐i concept. Curr Opin Allergy Clin Immunol 2002 Aug;2(4):301–5. Cross Ref link Pubmed link
  • 57  Gentile I, Talamo M, Borgia G. Is the drug‐induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy‐mediated viral reactivation? Report of a case and literature review. BMC Infect Dis [Case Reports Review] 2010;10:49. Pubmed link
  • 58  Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug‐induced multiorgan reaction in the same sequential order as in graft‐versus‐host disease. Br J Dermatol 2006 Aug;155(2):301–6. Cross Ref link Pubmed link
  • 59  Shiohara T, Inaoka M, Kano Y. Drug‐induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006 Mar;55(1):1–8. Cross Ref link Pubmed link
  • 60  Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med [Research Support, Non‐U.S. Government] 2010 Aug 25;2(46):46ra62. Cross Ref link Pubmed link
  • 61  Kano Y, Seishima M, Shiohara T. Hypogammaglobulinemia as an early sign of drug‐induced hypersensitivity syndrome. J Am Acad Dermatol 2006 Oct;55(4):727–8. Cross Ref link Pubmed link
  • 62  Chen Y‐C, Chang C‐Y, Cho Y‐T, Chiu H‐C, Chu C‐Y. Long‐term sequelae of drug reaction with eosinophilia and systemic symptoms: A retrospective cohort study from Taiwan. J Am Acad Dermatol 2013;68(3):459–65. Cross Ref link Pubmed link
  • 63  Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug‐induced hypersensitivity syndrome. Br J Dermatol [Case Reports Research Support, Non‐U.S. Government] 2007 Nov;157(5):934–40. Cross Ref link Pubmed link
  • 64  Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short‐ and long‐term outcomes of 34 patients with drug‐induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol 2013;68(5):721–8. Cross Ref link Pubmed link
  • 65  Chiou CC, Yang LC, Hung SI, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol 2008 Sep;22(9):1044–9. Cross Ref link Pubmed link
  • 66  Borroni G, Torti S, Pezzini C, et al. Histopathologic spectrum of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a diagnosis that needs clinico‐pathological correlation. G Ital Dermatol Venereol 2014 Jun;149(3):291–300. Pubmed link
  • 67  Chi MH, Hui RC, Yang CH, et al. Histopathologic analysis and clinical correlation of drug reaction with eosinophilia and systemic symptoms (DRESS). Br J Dermatol 2013;170(4):866–73. Cross Ref link
  • 68  Walsh S, Diaz‐Cano S, Higgins E, et al. Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol 2013 Feb;168(2):391–401. Cross Ref link Pubmed link
  • 69  Liao WP, Shi YW, Min FL. HLA‐B*1502 screening and toxic effects of carbamazepine. N Engl J Med 2011 Aug 18;365(7):672–3; author reply 3. Cross Ref link Pubmed link
  • 70  Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA‐B*1502 and carbamazepine‐induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010 May;51(5):926–30. Cross Ref link Pubmed link
  • 71  McCormack M, Alfirevic A, Bourgeois S, et al. HLA‐A*3101 and carbamazepine‐induced hypersensitivity reactions in Europeans. N Engl J Med 2011 Mar 24;364(12):1134–43. Cross Ref link Pubmed link
  • 72  Amstutz U, Shear NH, Rieder MJ, et al. Recommendations for HLA‐B*15:02 and HLA‐A*31:01 genetic testing to reduce the risk of carbamazepine‐induced hypersensitivity reactions. Epilepsia 2014 Apr;55(4):496–506. Cross Ref link Pubmed link
  • 73  Kaniwa N, Sugiyama E, Saito Y, et al. Specific HLA types are associated with antiepileptic drug‐induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics 2013 Nov;14(15):1821–31. Cross Ref link Pubmed link
  • 74  Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine‐hypersensitive patients. Neurology 2001 Apr 10;56(7):890–6. Cross Ref link Pubmed link
  • 75  Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001 Jun;22(6):298–305. Cross Ref link Pubmed link
  • 76  Barbaud A, Waton J, Herbeth B, et al. Comparison of cytokine gene polymorphism in drug‐induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS). J Eur Acad Dermatol Venereol 2014 Apr;28(4):491–9. Cross Ref link Pubmed link
  • 77  Elsheikh A, Lavergne SN, Castrejon JL, et al. Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism. J Immunol 2010 Dec 1;185(11):6448–60. Cross Ref link Pubmed link
  • 78  Anjum N, Polak ME, Ardern‐Jones M, Cooper HL. Presence of the HLA‐A*3101 allele in a familial case of drug reaction with eosinophilia and systemic symptoms, secondary to carbamazepine. Clin Exp Dermatol 2014 Apr;39(3):307–9. Cross Ref link Pubmed link
  • 79  Peyriere H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side‐effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol [Multicenter Study] 2006 Aug;155(2):422–8. Cross Ref link Pubmed link
  • 80  Kardaun SH, Sidoroff A, Valeyrie‐Allanore L, et al. Variability in the clinical pattern of cutaneous side‐effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol [Comment Letter] 2007 Mar;156(3):609–11. Cross Ref link Pubmed link
  • 81  Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007 May;156(5):1083–4. Cross Ref link Pubmed link
  • 82  Chen Y‐C, Chiu H‐C, Chu C‐Y. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol [Comparative Study] 2010 Dec;146(12):1373–9. Cross Ref link Pubmed link
  • 83  Mikami C, Ochiai K, Kagami M, Tomioka H, Tanabe E. In vitro interleukin‐5 (IL‐5) production by peripheral blood mononuclear cells from patients with drug hypersensitivity. J Dermatol 1996 Jun;23(6):379–81. Cross Ref link Pubmed link
  • 84  Mikami C, Ochiai K, Umemiya K, et al. Eosinophil activation and in situ interleukin‐5 production by mononuclear cells in skin lesions of patients with drug hypersensitivity. J Dermatol 1999 Oct;26(10):633–9. Cross Ref link Pubmed link
  • 85  Kano Y, Ishida T, Hirahara K, Shiohara T. Visceral involvements and long‐term sequelae in drug‐induced hypersensitivity syndrome. Med Clin North Am [Research Support, Non‐U.S. Government Review] 2010;94(4):743–59, xi. Cross Ref link Pubmed link
  • 86  Eshki M, Allanore L, Musette P, et al. Twelve‐year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol [Case Reports] 2009 Jan;145(1):67–72. Pubmed link
  • 87  Augusto JF, Sayegh J, Simon A, et al. A case of sulphasalazine‐induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol Dial Transplant 2009 Sep;24(9):2940–2. Cross Ref link Pubmed link
  • 88  Savard S, Desmeules S, Riopel J, Agharazii M. Linezolid‐associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Am J Kidney Dis 2009 Dec;54(6):e17–20. Cross Ref link Pubmed link
  • 89  Zuliani E, Zwahlen H, Gilliet F, Marone C. Vancomycin‐induced hypersensitivity reaction with acute renal failure: resolution following cyclosporine treatment. Clin Nephrol 2005 Aug;64(2):155–8. Cross Ref link Pubmed link
  • 90  Bourgeois GP, Cafardi JA, Groysman V, Hughey LC. A review of DRESS‐associated myocarditis. J Am Acad Dermatol 2012;66(6):e229–e36. Cross Ref link Pubmed link
  • 91  Bourgeois GP, Cafardi JA, Groysman V, et al. Fulminant myocarditis as a late sequela of DRESS: two cases. J Am Acad Dermatol 2011 Oct;65(4):889–90. Cross Ref link Pubmed link
  • 92  Lo MH, Huang CF, Chang LS, et al. Drug reaction with eosinophilia and systemic symptoms syndrome associated myocarditis: a survival experience after extracorporeal membrane oxygenation support. J Clin Pharm Ther 2013 Apr;38(2):172–4. Cross Ref link Pubmed link
  • 93  Arsenovic N, Sheehan L, Clark D, Moreira R. Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis. J Forensic Leg Med 2010 Feb;17(2):57–61. Cross Ref link Pubmed link
  • 94  Ang C‐C, Wang Y‐S, Yoosuff E‐LM, Tay Y‐K. Retrospective analysis of drug‐induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol 2010;63(2):219–27. Cross Ref link Pubmed link
  • 95  Sola D, Rossi L, Sainaghi PP, Pirisi M. DRESS syndrome with cerebral vasculitis. Intern Med 2013;52(12):1403–5. Cross Ref link Pubmed link
  • 96  Fujino Y, Nakajima M, Inoue H, Kusuhara T, Yamada T. Human herpesvirus 6 encephalitis associated with hypersensitivity syndrome. Ann Neurol [Case Reports] 2002;51(6):771–4. Cross Ref link Pubmed link
  • 97  Sakuma K, Kano Y, Fukuhara M, Shiohara T. Syndrome of inappropriate secretion of antidiuretic hormone associated with limbic encephalitis in a patient with drug‐induced hypersensitivity syndrome. Clin Exp Dermatol 2008 May;33(3):287–90. Cross Ref link Pubmed link
  • 98  Do‐Pham G, Charachon A, Duong TA, et al. Drug reaction with eosinophilia and systemic symptoms and severe involvement of digestive tract: description of two cases. Br J Dermatol [Case Reports Letter] 2011 Jul;165(1):207–9. Cross Ref link Pubmed link
  • 99  Balatsinou C, Milano A, Caldarella MP, et al. Eosinophilic esophagitis is a component of the anticonvulsant hypersensitivity syndrome: description of two cases. Digest Liver Dis [Case Reports] 2008;40(2):145–8. Cross Ref link
  • 100  Atkinson RJ, Dennis G, Cross SS, McAlindon ME, Sharrack B, Sanders DS. Eosinophilic colitis complicating anti‐epileptic hypersensitivity syndrome: an indication for colonoscopy? Gastrointest Endosc [Case Reports] 2004;60(6):1034–6. Cross Ref link Pubmed link
  • 101  Fervenza FC, Kanakiriya S, Kunau RT, Gibney R, Lager DJ. Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with lamotrigine treatment. Am J Kidney Dis [Case Reports] 2000;36(5):1034–40. Cross Ref link Pubmed link
  • 102  Eland IA, Dofferhoff AS, Vink R, Zondervan PE, Stricker BH. Colitis may be part of the antiepileptic drug hypersensitivity syndrome. Epilepsia [Case Reports] 1999;40(12):1780–3. Cross Ref link Pubmed link
  • 103  Schwartz RA, Husain Z, Reddy BY. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and dysphagia: a noteworthy association. J Am Acad Dermatol 2013 Dec;69(6):1058. Cross Ref link Pubmed link
  • 104  Descamps V. Dysphagia, a major early manifestation in DRESS syndrome. J Am Acad Dermatol 2013 Dec;69(6):1057–8. Cross Ref link Pubmed link
  • 105  Cookson H, Creamer D, Walsh S. Thyroid dysfunction in drug reaction with eosinophilia and systemic symptoms (DRESS): an unusual manifestation of systemic drug hypersensitivity. Br J Dermatol 2013 May;168(5):1130–2. Cross Ref link Pubmed link
  • 106  Seino Y, Yamauchi M, Hirai C, et al. A case of fulminant type 1 diabetes associated with mexiletine hypersensitivity syndrome. Diabet Med 2004 Oct;21(10):1156–7. Cross Ref link Pubmed link
  • 107  Chiou CC, Chung WH, Hung SI, Yang LC, Hong HS. Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection. J Am Acad Dermatol 2006 Feb;54(2 Suppl.):S14–17. Cross Ref link Pubmed link
  • 108  Sommers LM, Schoene RB. Allopurinol hypersensitivity syndrome associated with pancreatic exocrine abnormalities and new‐onset diabetes mellitus. Arch Intern Med 2002 May 27;162(10):1190–2. Cross Ref link Pubmed link
  • 109  Aota N, Hirahara K, Kano Y, Fukuoka T, Yamada A, Shiohara T. Systemic lupus erythematosus presenting with Kikuchi–Fujimoto's disease as a long‐term sequela of drug‐induced hypersensitivity syndrome. A possible role of Epstein–Barr virus reactivation. Dermatology 2009;218(3):275–7. Cross Ref link Pubmed link
  • 110  Aota N, Shiohara T. Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes. Autoimmun Rev 2009 May;8(6):488–94. Cross Ref link Pubmed link
  • 111  Bouvresse S, Valeyrie‐Allanore L, Ortonne N, et al. Toxic epidermal necrolysis, DRESS, AGEP: Do overlap cases exist? Orphanet J Rare Dis 2012;7(1):72. Cross Ref link Pubmed link
  • 112  Lee HY, Walsh S, Creamer D. Initial presentation of DRESS: often misdiagnosed as infections. Arch Dermatol 2012 Sep;148(9):1085–7. Cross Ref link Pubmed link
  • 113  Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003;4(8):561–72. Cross Ref link Pubmed link
  • 114  Mockenhaupt M. Severe drug‐induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009 Feb;7(2):142–60; quiz 61–2.
  • 115  Ogawa K, Morito H, Hasegawa A, et al. Identification of thymus and activation‐regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug‐induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS). J Dermatol Sci 2013 Jan;69(1):38–43. Cross Ref link Pubmed link
  • 116  Ogawa K, Morito H, Hasegawa A, et al. Elevated serum thymus and activation‐regulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reactions with eosinophilia and systemic symptoms (DRESS)/ drug‐induced hypersensitivity syndrome (DIHS). Br J Dermatol 2014;171(2):425–7. Cross Ref link Pubmed link
  • 117  Descamps V, Ben Said B, Sassolas B, et al. [Management of drug reaction with eosinophilia and systemic symptoms (DRESS).] Ann Dermatol Venereol 2010 Nov;137(11):703–8. Cross Ref link Pubmed link
  • 118  Natkunarajah J, Goolamali S, Craythorne E, et al. Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol [Comparative Study] 2011 May–Jun;21(3):385–91. Pubmed link
  • 119  Kito Y, Ito T, Tokura Y, Hashizume H. High‐dose intravenous immunoglobulin monotherapy for drug‐induced hypersensitivity syndrome. Acta Derm Venereol 2012 Jan;92(1):100–1. Cross Ref link Pubmed link
  • 120  Scheuerman O, Nofech‐Moses Y, Rachmel A, Ashkenazi S. Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immune globulin. Pediatrics 2001 Jan;107(1):E14. Cross Ref link Pubmed link
  • 121  Fields KS, Petersen MJ, Chiao E, Tristani‐Firouzi P. Case reports: treatment of nevirapine‐associated dress syndrome with intravenous immune globulin (IVIG). J Drugs Dermatol 2005 Jul–Aug;4(4):510–13. Pubmed link
  • 122  Joly P, Janela B, Tetart F, et al. Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol 2012 Apr;148(4):543–4. Cross Ref link Pubmed link
  • 123  Singer EM, Wanat KA, Rosenbach MA. A case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins. JAMA Dermatol 2013 Apr;149(4):494–5. Cross Ref link Pubmed link
  • 124  Santhamoorthy P, Alexander KJ, Alshubaili A. Intravenous immunoglobulin in the treatment of drug rash eosinophilia and systemic symptoms caused by phenytoin. Ann Indian Acad Neurol 2012 Oct;15(4):320–2. Cross Ref link Pubmed link
  • 125  Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004 Feb;140(2):183–8. Pubmed link
  • 126  Aihara Y, Ito SI, Kobayashi Y, Yamakawa Y, Aihara M, Yokota S. Carbamazepine‐induced hypersensitivity syndrome associated with transient hypogammaglobulinaemia and reactivation of human herpesvirus 6 infection demonstrated by real‐time quantitative polymerase chain reaction. Br J Dermatol 2003 Jul;149(1):165–9. Cross Ref link Pubmed link
  • 127  Sandouk Z, Alirhayim Z, Khoulani D, Hassan S. DRESS syndrome and thrombotic thrombocytopaenic purpura: are they related? BMJ Case Rep 2012 Nov 14;2012, pii: bcr2012007558. doi: 10.1136/bcr‐2012‐007558.
  • 128  Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS. Minocycline‐induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol 2010 Feb;62(2):315–18. Cross Ref link Pubmed link
  • 129  Laban E, Hainaut‐Wierzbicka E, Pourreau F, et al. Cyclophosphamide therapy for corticoresistant drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient with severe kidney and eye involvement and Epstein–Barr virus reactivation. Am J Kidney Dis 2010 Mar;55(3):e11–14. Cross Ref link Pubmed link
  • 130  Moling O, Tappeiner L, Piccin A, et al. Treatment of DIHS/DRESS syndrome with combined N‐acetylcysteine, prednisone and valganciclovir – a hypothesis. Med Sci Monit 2012 Jul;18(7):CS57–62. Cross Ref link

Drug‐induced generalized exfoliative dermatitis

  • 131  Khaled A, Sellami A, Fazaa B, et al. Acquired erythroderma in adults: a clinical and prognostic study. J Eur Acad Dermatol Venereol 2010;24:781–8. Cross Ref link Pubmed link
  • 132  Li J, Zheng HY. Erythroderma: a clinical and prognostic study. Dermatology 2012;225:154–62. Cross Ref link Pubmed link
  • 133  Nicolis GD, Helwig EB. Exfoliative dermatitis. A clinicopathologic study of 135 patients. Arch Dermatol 1973;108:788–97. Cross Ref link Pubmed link
  • 134  Sigurdsson V, Toonstra J, Hazemans‐Boer M, et al. Erythroderma – a clinical and follow‐up study of 102 patients with special emphasis on survival. J Am Acad Dermatol 1996;35:53–7. Cross Ref link Pubmed link
  • 135  Kardaun SH, Sekula P, Valeyrie‐Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169(5):1071. . Cross Ref link Pubmed link
  • 136  Fiszenson‐albala F, Auzerie V, Mahe E, et al. A 6‐month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003;149:1018–22. Cross Ref link Pubmed link
  • 137  Lee HY, Tay LK, Thirumoorthy T, Pang SM. Cutaneous adverse drug reactions in hospitalized patients. Singapore Med J 2010;51:767–74. Pubmed link
  • 138  . Fierro MT, Comessatti A, Quaglino P, et al. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sezary syndrome. Dermatology 2006;213:284–92. Cross Ref link Pubmed link
  • 139  Barbaud AM, Bene MC, Reichert‐Penetrat S, et al. Immunocompetent cells and adhesion molecules in 14 cases of cutaneous drug reactions induced with the use of antibiotics. Arch Dermatol 1998;134:1040–1. Cross Ref link Pubmed link
  • 140  Hung SI, Chung WH, Liou LB, et al. HLA‐B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134–9. Cross Ref link Pubmed link
  • 141  McCormack M, Alfirevic A, Bourgeois S, et al. HLA‐A*3101 and carbamazepine‐induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134–43. Cross Ref link Pubmed link
  • 142  . Walsh NMG, Prokopetz R, Tron VA, et al. Histopathology in erythroderma: review of a series of cases by multiple observers. J Cutan Pathol 1994;24:419–23. Cross Ref link
  • 143  Zip C, Murray S, Walsh NMG. The specificity of histopathology in erythroderma. J Cutan Pathol 1993;20:393–8. Cross Ref link Pubmed link
  • 144  Pal S, Haroon TS. Erythroderma: a clinic‐etiologic study of 90 cases. Int J Dermatol 1998;37:104–7. Cross Ref link Pubmed link
  • 145  Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: A clinical study of 97 cases. BMC Dermatol 2005;5:5. Cross Ref link Pubmed link
  • 146  Hasan T, Jansen CT. Erythroderma: a follow‐up of fifty cases. J Am Acad Dermatol 1983;8:836–40. Cross Ref link Pubmed link
  • 147  Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001;45:321–8. Cross Ref link Pubmed link
  • 148  Rym BM, Mourad M, Bechir Z, et al. Erythroderma in adults: a report of 80 cases. Int J Dermatol 2005;44:731–5. Cross Ref link Pubmed link
  • 149  Sehgai VN, Srivastava G. Exfoliative dermatitis: A prospective study of 80 patients Dermatologica 1986;173;278–84. Cross Ref link Pubmed link
  • 150  Zhang JC, Sun YT. Efavirenz‐induced exfoliative dermatitis. Scand J Infect Dis 2013;45:70–2. Cross Ref link Pubmed link
  • 151  Mahe E, Descamps V, Baikian B, et al. Acitretin‐induced erythroderma in a psoriatic patient. J Eur Acad Dermatol Venereol 2006;20:1133–4. Cross Ref link Pubmed link
  • 152  Cockayne SE, Glet RJ, Gawkrodger DJ, McDonagh AJG. Severe erythrodermic reactions to the proton pump inhibitors and lansoprazole. Br J Dermatol 1999;141:173–4. Cross Ref link Pubmed link
  • 153  Reynolds NJ, Jonmes SK, Crossley J, Harman RRM. Exfoliative dermatitis due to Nifedipine. Br J Dermatol 1989;121:401–4. Cross Ref link Pubmed link
  • 154  Vano‐Galvan S, Fernandez‐Guarino MM, Henriquez‐Santana A, De Las Heras E. Imatinib‐induced erythroderma mediated by an unusual non‐dose‐dependent mechanism. Eur J Dermatol 2007;17:538–9. Pubmed link
  • 155  Gallelli L, Ferraro M, Mauro GF, et al. Generalized exfoliative dermatitis induced by interferon alfa. Ann Pharmacother 2004;38:2173–4. Cross Ref link Pubmed link
  • 156  Yuan XY, Guo JY, Dang YP, et al. Erythroderma: a clinical‐etiological study of 82 cases. Eur J Dermatol 2010;20:373–7. Pubmed link
  • 157  Horiuchi Y. Propolis induced erythroderma. J Dermatol 2001;28:580–1. Cross Ref link Pubmed link

Stevens–Johnson syndrome/toxic epidermal necrolysis

  • 158  Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child 1922;24:526–33. Cross Ref link
  • 159  Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355–61. Cross Ref link Pubmed link
  • 160  Bastuji‐Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92–6. Cross Ref link Pubmed link
  • 161  Roujeau JC, Chosidow O, Saiag P, et al. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990;23:1039–58. Cross Ref link Pubmed link
  • 162  Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981–1985. Arch Dermatol 1990;126:37–42. Cross Ref link Pubmed link
  • 163  Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population‐based registry. J Clin Epidemiol 1996;49:769–73. Cross Ref link Pubmed link
  • 164  Saka B, Barro‐Traore F, Atadokpede FA, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in Sub‐Saharan Africa: a multi‐centric study in four countries. Int J Dermatol 2013;52(5):575–9. Cross Ref link Pubmed link
  • 165  Ting W, Stone MS, Racila D, et al. TEN‐like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan‐epidermolysis. Lupus 2004;13(12):941–50. Cross Ref link Pubmed link
  • 166  Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case–control analysis. Clin Pharmacol Ther 2010; 88:60–8. Cross Ref link Pubmed link
  • 167  Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006;55:27–33. Cross Ref link Pubmed link
  • 168  Schwartz RA, McDonagh PH, Lee BW. Toxic epidermal necrolysis. Part I: J Am Acad Dermatol 2013; 69:173, e1–13. Cross Ref link
  • 169  Viard‐Leveugle I, Gaide O, Jankovic D, et al. TNF‐alpha and IFN‐gamma are potential inducers of Fas‐mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 2013;133:489–98. Cross Ref link Pubmed link
  • 170  Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490–3. Cross Ref link Pubmed link
  • 171  Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens–Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006;97:272–80. Cross Ref link Pubmed link
  • 172  Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008;14:1343–50. Cross Ref link Pubmed link
  • 173  Saito N, Qiao H, Yanagi T, et al. An annexin A1‐FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med 2014;6:245ra95. Cross Ref link Pubmed link
  • 174  Mockenhaupt M, Viboud C, Dunant A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR‐study. J Invest Dermatol 2008;128:35–44. Cross Ref link Pubmed link
  • 175  Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600–7. Cross Ref link Pubmed link
  • 176  Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996;135:6–11. Cross Ref link Pubmed link
  • 177  Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumonia‐induced rash and mucositis as a syndrome distinct from Stevens Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol 2015;72:239–45. Cross Ref link Pubmed link
  • 178  Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 2004;428 (6982):486. Cross Ref link Pubmed link
  • 179  Hung SI, Chung WH, Liou LB, et al. HLA‐B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102(11):4134–9. Cross Ref link Pubmed link
  • 180  Tangamornsuksan W, Chaiyakumaprak N, Somkrua R, et al. Relationship between the HLA‐B*1502 allele and carbamazepine‐induced Stevens–Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta‐analysis. JAMA Dermatol 2013;149(9):1025–32. Cross Ref link Pubmed link
  • 181  Toh DS, Tan LL, Aw DC, et al. Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. Pharmacogenomics J 2014;14(4):316–21. Cross Ref link Pubmed link
  • 182  Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160–5. Cross Ref link Pubmed link
  • 183  Gueudry J, Roujeau JC, Binaghi M, et al. Risk factors for the development of ocular complications of Stevens–Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009;145:157–62. Pubmed link
  • 184  Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997;23:1237–44. Cross Ref link Pubmed link
  • 185  McIvor R, Zaidi J, Peters W, Hyland R. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehab 1996;17:237–409. Cross Ref link
  • 186  Vujic I, Shroff A, Grzelka M, et al. Mycoplasma pneumoniae‐associated mucositis – case report and systematic review of literature. J Eur Acad Dermatol Venereol 2015;29:595. Cross Ref link Pubmed link
  • 187  Bastuji‐Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity‐of‐illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149–53. Cross Ref link Pubmed link
  • 188  Power WJ, Ghoraishi M, Merayo‐Lloves J, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens–Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995;102:1669–76. Cross Ref link Pubmed link
  • 189  Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005;153:241–53. Cross Ref link Pubmed link
  • 190  de Prost N, Mekontso‐Dessap A, Valeyrie‐Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med 2014;42:118–28. Cross Ref link Pubmed link
  • 191  Powell N, Munro JM, Rowbotham D. Colonic involvement in Stevens–Johnson syndrome. Postgrad Med J 2006;82(968):e10. Cross Ref link Pubmed link
  • 192  Oplatek A, Brown K, Sens S, et al. Long‐term follow‐up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006;27:26–33. Cross Ref link Pubmed link
  • 193  Paquet P, Jacob E, Quatresooz P, Jacquemin D, Pierard GE. Delayed reepitheliasation and scarring deregulation following drug‐induced toxic epidermal necrolysis. Burns 2007;33:100–4. Cross Ref link Pubmed link
  • 194  Magina S, Lisboa C, Leal V, et al. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology 2003;207:33–6. Cross Ref link Pubmed link
  • 195  Fellahi A, Zonhair K, Amraoui A, Benchikhi H. Stevens–Johnson and Lyell syndromes: mucocutaneous and ocular sequels in 43 patients. Ann Dermatol Venereol 2011;138:88–92. Cross Ref link Pubmed link
  • 196  Gueudry J, Roujeau JC, Binaghi M, et al. Risk factors for the development of ocular complications of Stevens–Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009;145:157–62. Pubmed link
  • 197  De Rojas MV, Dart JK, Saw VP. The natural history of Stevens–Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 2007;91:1048–53. Cross Ref link Pubmed link
  • 198  Sedghizadeh PP, Kumar SK, Gorur A, et al. Toxic epidermal necrolysis with a rare long‐term oral complication requiring surgical intervention. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:e29–33. Cross Ref link Pubmed link
  • 199  Roujeau JC, Phlippoteau C, Koso M, et al. Sjogren‐like syndrome after drug‐induced toxic epidermal necrolysis. Lancet 1985;1:609–11. Cross Ref link Pubmed link
  • 200  Kamada N, Kinoshita K, Togawa Y, et al. Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti‐Ro/SS‐A and a review of the published work. J Dermatol 2006;33:616–22. Cross Ref link Pubmed link
  • 201  Misra SP, Dwivedi M, Misra V. Esophageal stricture as a late sequel of Stevens–Johnson syndrome in adults: incidental detection because of foreign body impaction. Gastrointest Endosc 2004;59:437–40. Cross Ref link Pubmed link
  • 202  Karnsakul W, Arkachaisri T, Atisoo K, et al. Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: an interplay of unbalanced immune regulatory mechanisms. Ann Hepatol 2006;5:116–19. Pubmed link
  • 203  Murphy MI, Brant WE. Hematocolpos caused by genital bullous lesions in a patient with Stevens–Johnson syndrome. J Clin Ultrasound 1998;26:52–4. Cross Ref link Pubmed link
  • 204  Emberger M, Lanschuetzer CM, Laimer M, et al. Vaginal adenosis induced by Stevens–Johnson syndrome. J Eur Acad Dermatol Venereol 2006;20:896–8. Pubmed link
  • 205  Butt TF, Cox AR, Lewis H, Ferner RE. Patient experiences of serious adverse drug reactions and their attitudes to medicines. Drug Saf 2011;34:319–28. Cross Ref link Pubmed link
  • 206  Mockenhaupt M, Norgauer J. Cutaenous adverse drug reactions. Stevens–Johnson syndrome and toxic epidermal necrolysis. J World Allergy Org 2002;14:143–50. Cross Ref link
  • 207  Bastuji‐Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity‐of‐illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149–53. Cross Ref link Pubmed link
  • 208  Guegan S, Bastuji‐Garin S, Poszepczynska‐Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006;126:272–6. Cross Ref link Pubmed link
  • 209  Trent JT, Kirsner RS, Romanelli P, et al. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004;140:890–2. Pubmed link
  • 210  Garcia‐Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens–Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323–7. Pubmed link
  • 211  Schulz JT, Sheridan RL, Ryan CM, et al. A 10‐year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199–204. Cross Ref link Pubmed link
  • 212  Ducic I, Shalom A, Rising W, et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002;110:768–73. Cross Ref link Pubmed link
  • 213  Brown D. How far would you go to save someone's skin? Dermatol Nursing 2009;8:10–19.
  • 214  John T, Foulks GN, John ME, et al. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology 2002;109:351–60. Cross Ref link Pubmed link
  • 215  Shammas MC, Lai EC, Sarkar JS, et al. Management of acute Stevens–Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol 2010;149:203–13 +e2. Cross Ref link Pubmed link
  • 216  Hsu M, Jayaram A, Verner R, et al. Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens–Johnson syndrome and toxic epidermal necrolysis: a case–control study. Cornea 2012;31:1394–402. Cross Ref link Pubmed link
  • 217  Shay E, Kheirkhah A, Liang L, et al. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens–Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol 2009;54:686–96. Cross Ref link Pubmed link
  • 218  Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res 2010;31:100–4. Cross Ref link Pubmed link
  • 219  Coss‐Bu JA, Jefferson LS, Levy ML, et al. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract 1997;12:81–4. Cross Ref link Pubmed link
  • 220  De Sica Chapman A, Williams G, Soni N, et al. Granulocyte colony‐stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN protocol. Br J Dermatol 2010;162:860–5. Cross Ref link Pubmed link
  • 221  De Prost N, Ingen Housz Oro S, Duong Tu A, et al. Bacteremia in Stevens–Johnson syndrome and toxic epidermal necrolysis: Epidemiology, risk factors, and predictive value of skin cultures. Medicine 2010;89:28–36. Cross Ref link Pubmed link
  • 222  Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586–9. Cross Ref link Pubmed link
  • 223  Schwartz RA, McDonagh PH, Lee BW. Toxic epidermal necrolysis. Part II. J Am Acad Dermatol 2013;69:187.e1–16. Pubmed link
  • 224  Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008;58:33–40. Cross Ref link Pubmed link
  • 225  Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN‐based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 2005;85:497–502. Pubmed link
  • 226  Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS): experience with high‐dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007;33:452–9. Cross Ref link Pubmed link
  • 227  Trent JT, Kirsner RS, Romanelli P, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003;139:39–43. Pubmed link
  • 228  Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high‐dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26–32. Cross Ref link Pubmed link
  • 229  Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33–6. Pubmed link
  • 230  Campione E, Marulli GC, Carrozzo AM, et al. High‐dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003;83:430–2. Pubmed link
  • 231  Al‐Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004;43:847–51. Cross Ref link Pubmed link
  • 232  Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81–8. Cross Ref link Pubmed link
  • 233  Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246–55. Cross Ref link Pubmed link
  • 234  Tan AW, Thong BY, Yip LW, et al. High‐dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 2005;32:1–6. Cross Ref link Pubmed link
  • 235  Gravante G, Delogu D, Marianetti M, et al. Toxic epidermal necrolysis and Steven Johnson syndrome: 11‐years experience and outcome. Eur Rev Med Pharmacol Sci 2007;11:119–27. Pubmed link
  • 236  Firoz BF, Henning JS, Zarzabal LA, et al. Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol 2012;67:630–5. Cross Ref link Pubmed link
  • 237  Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta‐analysis. Br J Dermatol 2012;167:424–32. Cross Ref link Pubmed link
  • 238  Hirahara K, Kano Y, Sato Y, et al. Methylprednisolone pulse therapy for Stevens–Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. J Am Acad Dermatol 2013;69:496–8. Cross Ref link Pubmed link
  • 239  Ducic I, Shalom A, Rising W, et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002;110:768–73. Cross Ref link Pubmed link
  • 240  Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens–Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007;87:144–8. Cross Ref link Pubmed link
  • 241  Tripathi A, Ditto AM, Grammer LC, et al. Corticosteroid therapy in an additional 13 cases of Stevens–Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000;21:101–5. Cross Ref link Pubmed link
  • 242  Yang Y, Xu J, Li F, et al. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens–Johnson syndrome: a retrospective comparative study in China. Int J Dermatol 2009;48:1122–8. Cross Ref link Pubmed link
  • 243  Chen J, Wang B, Zeng Y, et al. High‐dose intravenous immunoglobulins in the treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol 2010;20:743–7. Pubmed link
  • 244  Murphy JT, Purdue GF, Hunt JL. Toxic epidermal necrolysis. J Burn Care Rehabil 1997;18:417–20. Cross Ref link Pubmed link
  • 245  Arevalo JM, Lorente JA, Gonzalez‐Herrada C, et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000;48:473–8. Cross Ref link Pubmed link
  • 246  Valeyrie‐Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010;163:847–53. Cross Ref link Pubmed link
  • 247  Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol 2013;79:686–92. Cross Ref link Pubmed link
  • 248  Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens–Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol 2014;71(5):941. Cross Ref link Pubmed link
  • 249  Narita YM, Hirahara K, Mizukawa Y, et al. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol 2011;38:236–45. Cross Ref link Pubmed link
  • 250  Kostal M, Blaha M, Lanska M, et al. Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases. J Clin Apher 2012;27:215–20. Cross Ref link Pubmed link
  • 251  Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol 2014;71:278–83. Cross Ref link Pubmed link